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treated early. It includes cancers of the 
fl oor of the mouth, tongue, cheeks, lips, 
sinuses, throat, etc. Smoking, chewing 
tobacco, alcohol consumption, diet 
(red and processed meat, fried foods), 
gastro-esophageal refl ux disease, human 
papillomavirus, and exposure to cer-
tain chemicals (e.g. asbestos, sulfuric 
acid, and formaldehyde) are some of 
the common causes behind the onset of 
OC. [ 1,2 ] These high risk factors are known 
to alter the expression of p16, APC, and 
p53 genes and account for the origin of 
OC. [ 3 ] Most patients do not show any 
symptoms at the early stage. However, 
with passage of time, symptoms like 
mouth ulcer, loosening of teeth, and 
hoarse voice are known to develop. [ 1 ] 
 Many techniques, including laser capture microdissection, 
visualization adjuncts, cytopathology, and biopsy, are being used 
for detection and monitoring of OC. [ 4–6 ] These methods are inva-
sive, time-consuming, expensive, and labor-intensive. In this 
context, biosensors offer a reliable, user-friendly, increased assay 
speed, high sensitivity and require low sample volumes. [ 7,8 ] 
 Among the various nanomaterials, the nanostructured metal 
oxides have recently aroused much interest since these inter-
esting materials provide high surface area for effective immo-
bilization of desired biomolecules with desired orientation. [ 9 ] In 
this context, nanostructured zirconium oxide (ZrO 2 ) has been 
found to have interesting characteristics for biosensing applica-
tions. These characteristics include biocompatibility, excellent 
electrical, and surface charge properties that can be benefi cial 
for integration of the immobilized biomolecules. Furthermore, 
oxygen moieties in ZrO 2 may facilitate covalent attachment of 
both silane compound and indium tin oxide coated glass (ITO) 
surface. [ 10–12 ] 
 The detection of cancer via biomarkers has been recently 
proposed. [ 13 ] In this context, the biomarkers, such as inter-
leukin-8 (IL-8), interleukin-6 (IL-6), vascular endothelial growth 
factor (VEGF) and epidermal growth factor receptor (EGFR) are 
currently being used for detection of oral cancer. [ 14–17 ] The OC 
detection via these biomarkers is currently a challenge since 
these are secreted at very low concentration (≈pg mL −1 ) and 
the biosensors proposed for the detection of these biomarkers 
require serum samples and are thus invasive. [ 14–17 ] Thus, 
 Results of the studies are reported relating to application of the silanized 
nanostructured zirconia, electrophoretically deposited onto indium tin oxide 
(ITO) coated glass for covalent immobilization of the monoclonal antibodies 
(anti-CYFRA-21-1). This biosensing platform has been utilized for a simple, 
effi cient, noninvasive, and label-free detection of oral cancer via cyclic voltam-
metry technique. The results of electrochemical response studies conducted 
on bovine serum albumin (BSA)/anti-CYFRA-21-1/3-aminopropyl triethoxy 
silane (APTES)/ZrO 2 /ITO immunoelectrode reveal that this immunoelectrode 
can be used to measure CYFRA-21-1 (oral cancer biomarker) concentration in 
saliva samples, with a high sensitivity of 2.2 mA mL ng −1 , a linear detection 
range of 2–16 ng mL −1 , and stability of six weeks. The results of these studies 
have been validated via enzyme-linked immunosorbent assay. 
This is an open access article under the terms of the Creative Commons 
Attribution License, which permits use, distribution and reproduction in 
any medium, provided the original work is properly cited.
 1.  Introduction 
 Oral cancer (OC) is presently one of the most prevalent can-
cers known till date, and it occurs more often in men than 
women. OC occurs as a sore in the mouth that does not easily 
heal. This cancer can be life threatening if not detected and 
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detection of OC biomarkers in human saliva samples provides 
a noninvasive and pain-free alternative. 
 CYFRA-21-1 is a water-soluble proteinaceous biomarker [ 18 ] 
that represents a fragment of 40 kD of cytokeratin 19. [ 19 ] The 
cutoff concentration of CYFRA-21-1 in saliva for normal 
subjects is 3.8 ng mL −1 , whereas oral cancer patients have 
been found to have CYFRA-21-1 concentration as high as 
17.46 ± 1.46 ng mL −1 . [ 18,20 ] The recent developments in clinical 
research have identifi ed salivary CYFRA-21-1, a reliable bio-
marker for the detection of OC. [ 18,20 ] To the best of our knowl-
edge, there is no report till date pertaining to a biosensor for 
detection of OC via salivary CYFRA-21-1. Compared to the lower 
levels (≈pg mL −1 ) of afore-mentioned biomarkers, CYFRA-21-1 
is present in high concentration (≈ng mL −1 ), in saliva. Addition-
ally, a biosensor for detection of CYFRA-21-1 from saliva sam-
ples is an attractive alternative with the immense potential for 
developing the biosensor for in-home testing. [ 21 ] 
 Efforts have been made for the detection of OC utilizing 
biosensor platforms. [ 14–17 ] Yang et al. reported electrochemical 
biosensor for the detection of trace level of salivary IL-8 pro-
tein. [ 15 ] To achieve low level of detection, streptavidin and HRP 
labeling of the receptor biomolecules has been proposed which 
increases the complexity of detection. [ 15 ] In another approach, 
CaCO 3 nanoparticles based biosensor has been reported for 
IL-6 detection in serum samples. [ 17 ] Apart 
from being invasive, this method is compli-
cated since it requires tagging of the receptor 
biomolecule. 
 We report results of the studies relating 
to development of a simple, label-free and 
noninvasive anti-CYFRA-21-1-based electro-
chemical biosensor based on ZrO 2 as trans-
ducer surface for OC detection in saliva sam-
ples. The results obtained using this electro-
chemical biosensor have been validated by 
performing enzyme-linked immunosorbent 
assay (ELISA). [ 18,20 ] 
 2.  Results and Discussion 
 2.1. Structural and Morphological Studies 
 X-ray diffraction (XRD) pattern of the syn-
thesized product is shown in  Figure  1 . The 
diffraction peaks corresponding to (110), 
(111), (1 11), (022), (200), ( 102), ( 2 11), 
(022), (122), (300), (013), (302), ( 1 13), 
and ( 2 22) planes are well indexed with 
JCPDS NO. 37-1484, indicating the for-
mation of the monoclinic crystal phase of 
ZrO 2 [ 22 ] and no peak corresponding to any 
impure phase is found in the XRD pattern. 
The XRD pattern of nanostructured zir-
conia samples prior to calcination is given 
in Figure S1 (Supporting Information), 
wherein an additional peak is observed at 
30.37° due to (111) refl ection of the sodium 
ethoxide (JCPDF No. 31-1885), formed as 
an intermediate product ( Scheme  1 a). However, after calcina-
tion, this peak disappears suggesting removal of the impuri-
ties. It can be seen (Figure S1, Supporting Information) that 
www.MaterialsViews.com
www.advancedscience.com
Adv. Sci. 2015, 2, 1500048
 Figure 1.  XRD pattern of the ZrO 2 nanoparticles.
 Scheme 1.  a) Synthesis mechanism of ZrO 2 nanoparticles and b) schematic of the fabrication 
of BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO immunoelectrode for detection of oral cancer.
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the (111) plane has the highest intensity revealing that the 
crystallites are grown more orderly along the (111) plane. The 
average crystallite size  “D” has been estimated to be ≈50 nm 
using the Scherer formula (Equation  ( 1) )
 
λ
β θ=
0.9
cos
D
 
(1)
 
 where  λ = 1.54060 Å is the wavelength of the target Cu-Kα,  θ 
is the Bragg’s diffraction angle, and  β is the full width at half 
maximum (FWHM) of the diffraction peak. 
 The size and shape of the ZrO 2 nanoparticles have been 
investigated using transmission electron microscope (TEM) 
( Figure  2 a,b). The TEM image of the nanoparticles reveals that 
particles have hexagonal and sheet-type structure. The indi-
vidual ZrO 2 nanoparticles have been selected for HR-TEM 
analysis (Figure  2 c). The HR-TEM image suggests that these 
particles are polycrystalline in nature. The lattice fringes with a 
 d- spacing of 0.318 nm corresponding to (111) planes are clearly 
visible. These observations are in agreement with the  d -values 
calculated for the respective planes from the XRD studies. 
In order to analyze the size distribution quantitatively, the 
histogram is fi tted with the Gaussian func-
tion and the mean size of the particle is cal-
culated to be 50 nm (Figure  2 d). 
 The results of surface morphology studies 
conducted on APTES/ZrO 2 /ITO, anti-
CYFRA-21-1/APTES/ZrO 2 /ITO, and BSA/
anti-CYFRA-21-1/APTES/ZrO 2 /ITO electrodes 
via atomic force microscopy (AFM) are shown 
in  Figure  3 a–c. The AFM image of the APTES/
ZrO 2 /ITO fi lm (Figure  3 a) shows smooth sur-
face with an average roughness of ≈1.9 nm. 
This suggests the formation of a uniform layer 
due to intermolecular interaction between 
APTES/ZrO 2 and ITO surfaces. Figure  3 b 
shows AFM image of the anti-CYFRA-21-1 
immobilized on APTES/ZrO 2 /ITO electrode 
surface with average roughness of ≈16.9 nm. 
The increased roughness may be attributed to 
globular Y-shaped structure of the antibodies 
and the immobilization of BSA onto the sur-
face of anti-CYFRA-21-1/APTES/ZrO 2 /ITO, 
resulting in decrease of the surface roughness 
to ≈2.7 nm (Figure  3 c). The decreased rough-
ness may be attributed to the nonspecifi c 
adsorption of BSA onto exposed APTES/ ZrO 2 sites. Figure S2 
(Supporting Information) shows side view of the SEM image of 
electrophoretically deposited APTES/ZrO 2 /ITO fi lm indicating 
presence of the uniformly dispersed grains of APTES function-
alized ZrO 2 nanoparticles at ITO substrate. However, in case of 
anti-CYFRA-21-1/APTES/ZrO 2 /ITO bioelectrode the granular 
morphology becomes globular due to covalent attachment of anti-
bodies to the APTES/ZrO 2 . Further, due to high anti-CYFRA-21-1 
loading, the individual grains of nanoparticles are not observed. 
 2.2. Fourier Transformed Infrared Spectroscopic 
(FT-IR) and X-Ray Photoelectron Spectroscopy (XPS) Studies 
 FT-IR spectrum ( Figure  4 ) of APTES/ZrO 2 /ITO electrode exhibits 
characteristic peaks at 540 cm −1 due to symmetric stretching of 
the Zr O bonds. [ 23 ] The bands seen between 950 and 1250 cm −1 
are due to Si O Zr and Si O C modes. [ 24 ] The bands found 
at 1566 and 1629 cm −1 are due to scissor and stretching mode of 
NH 2 present in the APTES. [ 24 ] Furthermore, a broad band present 
at 3377 cm −1 can be ascribed to the N H stretching vibration 
along with OH stretching of water mole cules. It may be noted 
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 Figure 2.  a,b) TEM image, c) HR-TEM image, and d) particle size distributionof ZrO 2 
nanoparticles.
 Figure 3.  AFM image of a) APTES/ZrO 2 /ITO electrode, b) anti-CYFRA-21-1/APTES/ZrO 2 /ITO bioelectrode, and c) BSA/anti-CYFRA-21-1/APTES/ZrO 2 /
ITO bioelectrode.
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that intensity of the 1566 and 1629 cm −1 bands (corresponding 
to -NH 2 of APTES/ZrO 2 /ITO) is considerably reduced in case of 
anti-CYFRA-21-1/APTES/ZrO 2 /ITO. These results reveal cova-
lent attachment of antibodies with amino terminal of APTES/
ZrO 2 /ITO. The band seen at 1400 cm −1 is due to bending vibra-
tion of the CH 2 aliphatic moiety of antibodies. Further, bands 
at 1538 and 1740 cm −1 correspond to amide II and C   O 
stretching (carboxylic group) of the antibody molecules. [ 24–26 ] 
 Analysis of the XPS studies was performed by fi rst calibrating 
the binding energy (BE) levels to the C 1s spectrum, using the 
sp 3 carbon (C C) peak from adventitious carbon at 284.8 eV. 
 Figure  5 a–c shows XPS of Zr 3d spectrum of ZrO 2 , APTES/
ZrO 2 and anti-CYFRA-21-1/APTES/ZrO 2 /ITO electrodes. The 
XPS spectra of all three samples have been deconvoluted into 
the corresponding binding energy peaks. The observed spin–
orbit doublet peaks seen at around 181.9 and 184.2 eV cor-
respond to Zr 3d 5/2 and Zr 3d 3/2 electrons, respectively, and 
are due to the presence of Zr in its oxidized state, Zr 4+ from 
ZrO 2 . [ 27 ] Figure  5 d shows O 1s spectrum of ZrO 2 containing a 
maximum around 530 eV suggesting the presence of electrons 
from oxygen in the O 2− state from ZrO 2 . Further, the peak seen 
at higher binding energy position of 531.0 eV may perhaps be 
due to other chemical states of oxygen (C-O or C=O). Figure  5 e 
shows the O 1s spectrum of APTES modifi ed ZrO 2 where two 
peaks at 530.0 and 532.2 eV are observed. The peak at higher 
binding energy (532.2 eV) is assigned to the oxygen atom 
linked to silicon, while the other one at lower binding energy 
(530.0 eV) is attributed to the oxygen in ZrO 2 . [ 28 ] In case of 
the anti-CYFRA-21-1/APTES/ZrO 2 /ITO immunoelectrode, the 
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 Figure 4.  FT-IR spectra of APTES/ZrO 2 /ITO and anti-CYFRA-21-1/
APTES/ZrO 2 /ITO electrode.
 Figure 5.  Zr 3d XPS spectra of a) ZrO 2 , b) APTES/ZrO 2 , c) anti-CYFRA-21-1/APTES/ZrO 2 , O 1s spectra of d) ZrO 2 , e) APTES/ZrO 2 , f) anti-CYFRA-21-1/ 
APTES/ZrO 2 , N 1s spectra of g) APTES/ZrO 2 and h) anti-CYFRA-21-1/APTES/ZrO 2 .
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deconvoluted O 1s spectrum (Figure  5 f) shows binding energy 
peaks around 530.8, 532.2, and 536.0 eV. The additional peak 
at 536.0 eV is attributed to the amide oxygen present in the 
antibody molecules. Figure  5 g shows nitrogen core level XPS 
of APTES modifi ed ZrO 2 where the BE peak seen at 399.2 eV 
is attributed to the nitrogen present in the APTES. In case of 
the anti-CYFRA-21-1/APTES/ZrO 2 /ITO, three distinct peaks 
are observed at 399.5, 400.3, and 401.5 eV (Figure  5 h). The peak 
observed at the binding energy of 401.5 eV is attributed to the 
≡N species, whereas another peak seen at lower binding energy 
of 400.3 eV corresponds to amide nitrogen (OC NH) present 
in the antibody molecules. [ 29 ] 
 2.3.  Electrochemical Studies 
 Figure  6 shows results of differential pulse voltammetry 
(DPV) studies conducted on ITO, APTES/ZrO 2 /ITO, anti-
CYFRA-21-1/APTES/ZrO 2 /ITO, and BSA/anti-CYFRA-21-1/
APTES/ZrO 2 /ITO electrodes, respectively. It can be seen that 
magnitude of current obtained for APTES/ZrO 2 /ITO electrode 
(0.082 mA) is lower than that of bare ITO electrode (0.229 mA), 
indicating decreased electron transfer between solution and 
APTES/ZrO 2 /ITO interface. However, after the immobiliza-
tion of anti-CYFRA-21-1 onto the APTES/ZrO 2 /ITO electrode, 
the magnitude of peak current (0.176 mA) increases and the 
peak potential shifts to a lower value indicating facile electron 
transfer to the electrode surface. The magnitude of current 
response increases after anti-CYFRA-21-1 functionalizes the 
APTES/ZrO 2 /ITO electrode surface. The APTES/ZrO 2 per-
haps acts as a mediator on the electrode surface and it can 
signifi cantly shorten the electron tunneling distance between 
the antibodies and the electrode resulting in a higher current. 
Besides this, the electrostatic interaction between the free site 
of the antibodies (-NH 2 terminal) and the redox species may 
result in fast electron diffusion toward the immunoelectrode. [ 30 ] 
After BSA immobilization, the magnitude of current decreases 
to 0.156 mA. This is due to nonspecifi c adsorption of BSA onto 
the exposed APTES/ZrO 2 sites of the anti-CYFRA-21-1/APTES/
ZrO 2 /ITO immunoelectrode. After the BSA treatment, the peak 
potential shifts toward the higher value due to insulating char-
acteristics of the BSA molecules. 
 The effect of pH on the electrochemical response of the 
BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO electrode has been 
investigated using cyclic voltammetry (CV) at scan rate 
of 20 mV s −1 in phosphate buffer saline (PBS) containing 
5 × 10 −3 M [Fe(CN) 6 ] 3−/4− . It can be seen that magnitude of the 
current response is maximum at neutral pH (7.0) (Figure S3, 
Supporting Information). This may perhaps be due to the 
fact that biological molecules such as amino acid, enzyme, 
antigen, antibody, etc. are present in natural form with high 
activity at neutral pH. However, in acidic or basic medium 
antibodies get denatured due to the interaction of H + or 
OH − ion on amino acid sequence of antibodies. [ 31,32 ] Con-
sequently, all electrochemical studies have been conducted 
using PBS of pH 7.0 with 5 × 10 −3 M [Fe(CN) 6 ] 3−/4− . Figures S4 
and S5 (Supporting Information) show CV response of 
APTES/ZrO 2 /ITO and BSA/anti-CYFRA-21-1/APTES/ZrO 2 /
ITO electrode as a function of scan rate (10–100 mV s −1 ), 
respectively. We observe that both cathodic ( I pc ) and anodic 
( I pa ) peak current vary linearly with square root of the scan 
rate (insets a) in Figures S4 and S5 in the Supporting Infor-
mation), indicating that electrochemical reaction is a diffu-
sion-controlled process. [ 30 ] The slopes and intercepts are 
given by Equations  ( 2) – ( 5) 
 
I
R
[9.32 A(smV )
(scan rate[mVs ]) ] 7.96 A, 0.998
pc(APTES/ZrO /ITO)
1
1 1/2 2
2 μ
μ
=
× + =
−
−
 
(2)
 
 
I
R
[8.43 A(smV )
(scan rate[mVs ]) ] 8.29 A, 0.999
pa(APTES/ZrO /ITO)
1
1 1/2 2
2 μ
μ
= −
× − =
−
−
 
(3)
 
 
I
R
[52.54 A(smV )
(scan rate[mVs ]) ] 19.60 A, 0.992
pc(BSA/anti-CYFRA-21-1/APTES/ZrO /ITO)
1
1 1/2 2
2 μ
μ
=
× + =
−
−
 
(4)
 
 
I
R
[44.50 A(smV )
(scan rate[mVs ]) ] 80.60 A, 0.996
pa(BSA/anti-CYFRA-21-1/APTES/ZrO /ITO)
1
1 1/2 2
2 μ
μ
= −
× − =
−
−
 
(5)
 
 The difference of cathodic ( E pc ) and anodic ( E pa ) peak poten-
tials (Δ E p = E pc − E pa ) and square root of scan rate for APTES/
ZrO 2 /ITO and BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO elec-
trodes exhibit a linear relationship and are given by Equa-
tions  ( 6) and  ( 7) . A good linear fi tting suggests a facile electron 
transfer from medium to electrode (inset b in Figures S4 and 
S5 in the Supporting Information)
 
E V
R
( ) [0.035V(smV )
(scan rate[mVs ]) ] 0.10V, 0.995
p APTES/ZrO /ITO
1
1 1/2 2
2Δ =
× + =
−
−
 
(6)
 
 
E V
R
( ) [0.035V(smV )
(scan rate[mVs ]) ] 0.27V, 0.992
p BSA/anti-CYFRA-21-1/APTES/ZrO /ITO
1
1 1/2 2
2Δ =
× + =
−
−
 
(7)
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 Figure 6.  Differential pulse voltammogram (DPV) of a) ITO, b) APTES/
ZrO 2 /ITO, c) anti-CYFRA-21-1/APTES/ZrO 2 /ITO, and d) BSA/anti-
CYFRA-21-1/APTES/ZrO 2 /ITO electrodes.
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 Figure S6 (Supporting Information) shows the variation of 
current obtained via CV on interaction of CYFRA-21-1 with the 
BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO immunoelectrode for 
different incubation times. We observe an increase in current 
with respect to incubation time from 2 to 20 min. However, 
after 20 min of sample incubation the current becomes nearly 
constant. Thus, we have selected the sample incubation time 
as 20 min during which the antigen–antibody binding reaction 
reaches the steady state. 
 2.4.  Response Studies 
 The electrochemical response of BSA/anti-CYFRA-21-1/APTES/
ZrO 2 /ITO immunoelectrode has been measured as a function of 
CYFRA-21-1 concentration (2–16 ng mL −1 ) in PBS (50 × 10 −3 M , 
pH 7.0, 0.9%NaCl) containing [Fe(CN) 6 ] 3−/4− (5 × 10 −3 M ) at 
20 mV s −1 (scan rate) using the CV technique ( Figure  7 ). All the 
measurements have been repeated three times for each concen-
tration. It can be seen that magnitude of the oxidation current 
increases with increase in concentration of CYFRA-21-1. This 
electrochemical response behavior can be assigned to the for-
mation of an antigen–antibody complex between CYFRA-21-1 
and anti-CYFRA-21-1 antibody on the surface of the immu-
noelectrode resulting in the formation of an electron transfer 
accelerating layer. [ 33 ] Under optimized assay conditions, the 
calibration curve using CYFRA-21-1 standard shows a linear 
response from the BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO 
immunoelectrode in the concentration range of 2–16 ng mL −1 
(Figure  7 , inset b) with a linear regression coeffi cient of 0.995 
as given in following equation
 
I
R
[2.2 mA mL ng ) (conc. of CYFRA-21-1(ngmL ))]
0.278 mA, 0.995
p
1 1
2
= ×
+ =
− −
 
(8)
 
 The sensitivity of the fabricated BSA/anti-CYFRA-21-1/
APTES/ZrO 2 /ITO immunoelectrode has been estimated to be 
2.2 mA mL ng −1 and the lower detection limit (LD) has been 
determined to be 0.08 ng mA −1 mL −1 using Equation  ( 9) 
 mDetection limit 3 /bσ=  (9) 
 where  σ b is standard deviation and  m is the slope of the 
curve. 
 A control experiment has been conducted using the APTES/
ZrO 2 /ITO electrode as a function of CYFRA-21-1 concentra-
tion (Figure S7, Supporting Information). We do not observe 
any signifi cant change in the current response of the APTES/
ZrO 2 /ITO electrode with increasing concentration of CYFRA-
21-1 antigen. It appears that the APTES/ZrO 2 /ITO electrode 
surface does not interact with antigen molecule and therefore 
the electrochemical current remains unchanged. Next, we have 
performed the interferent studies conducted on BSA/anti-
CYFRA-21-1/APTES/ZrO 2 /ITO immumoelectrode using var-
ious potentially interfering substances (Figure S8, Supporting 
Information). Human saliva contains various analytes, such 
as carcinoembroyonic antigen (CEA) [4–16 ng mL −1 ], cardiac 
troponin I (Tn-I) [0.19 ng mL −1 ], sodium carboxymethyl cellu-
lose (NaCMC) [10 mg mL −1 ], glucose [7 mg mL −1 ], etc. We fi nd 
that magnitude of the oxidation current decreases by 0.14%, 
1.3%, 1.68%, and 1.75% upon addition of CEA, NaCMC, Tn-I, 
and glucose, respectively, indicating high selectivity of the 
biosensor. 
 The shelf-life of BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO 
immunoelectrode (Figure S9, Supporting Information) has 
been determined by measuring the CV response in standard 
solution of CYFRA-21-1 (6 ng mL −1 ) in PBS at one week 
interval. It is found that no signifi cant change occurs in the 
peak current up to about six weeks after which decrease in the 
response current is observed. 
 The effect of addition of different amount of saliva sample on 
the response current was investigated and shown in Figure S10 
(Supporting Information). Here, we have taken different quan-
tities of artifi cial saliva [ 34 ] (prepared as reported elsewhere) 
and observed the effect on electrochemical response of BSA/
anti-CYFRA-21-1/APTES/ZrO 2 /ITO immunoelectrode. It has 
been observed that electrochemical response was stable up to 
addition of 1000 µL artifi cial saliva and thereafter it tends to 
decrease toward higher concentration. 
 2.5.  Real Sample Analysis 
 Quantifi cation of CYFRA-21-1 in saliva sample has been 
accomplished by ELISA in triplicate. The double-antibody 
sandwich ELISA is performed in microtiter wells precoated 
with anti-CYFRA-21-1. After following all the steps, colori-
metric reaction occurs and absorbance is recorded at 450 nm 
in ELISA plate reader. A series of CYFRA-21-1 concentration 
in saliva samples obtained by ELISA ( Table  1 ) have been used 
to test the accuracy of the fabricated biosensor. It can be seen 
that a reasonable correlation exists between magnitude of 
the CV current response of the fabricated immunoelectrode 
in the presence of (a) CYFRA-21-1 concentrations in saliva 
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 Figure 7.  Electrochemical response of BSA/anti-CYFRA-21-1/APTES/
ZrO 2 /ITO immunoelectrode as a function of CYFRA-21-1 concentration 
(2–16 ng mL −1 ). The magnifi ed view of oxidation peak current (inset a)), 
calibration curve between magnitude of peak current and concentration 
of CYFRA-21-1 (ng mL −1 ) (inset b)).
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samples determined by ELISA and (b) standard concentration 
of CYFRA-21-1 (Table 1 and Figure S11, Supporting Informa-
tion). The observed results exhibit acceptable %RSD (relative 
standard deviation) indicating high accuracy of the fabricated 
biosensor. The sensing characteristics of proposed immu-
nosensor have been summarized in  Table  2 along with those 
reported in the literature. 
 3.  Conclusion 
 We have fabricated a simple, effi cient, label-free, and noninva-
sive nanostructured zirconia based biosensing platform for oral 
cancer detection. ZrO 2 nanoparticles have been synthesized 
via the hydrothermal method and its silanization has been 
achieved using APTES. Thin fi lms of APTES/ZrO 2 /ITO have 
been fabricated via electrophoretic deposition and followed by 
covalent immobilization of antibodies. The salivary CYFRA-21-1 
antigen has been used as a biomarker for the detection of oral 
cancer. In comparison with other reported oral cancer detec-
tion methods including biosensors, the BSA/anti-CYFRA-21-1/
APTES/ZrO 2 /ITO biosensor is simple, exhibits a wider detec-
tion range of 2–16 ng mL −1 high sensitivity of 2.2 mA mL ng −1 , 
detection limit of 0.08 ng mL −1 , and shelf-life of six weeks. This 
novel saliva based oral cancer biomarker (CYFRA-21-1) opens a 
new window for noninvasive research in oral and other cancers. 
 4.  Experimental Section 
 Reagents : Zirconium ethoxide [Zr(C 2 H 5 OH) 4 ] and 
1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride 
(EDC) [C 8 H 17 N 3 ] of AR grade were purchased from Sigma-Aldrich. 
Sodium hydroxide (NaOH) pellets, cetyltrimethylammonium bromide 
(CTAB) [C 19 H 42 BrN], sodium monophosphate [NaH 2 PO 4 ], sodium 
diphosphatedihydrate [Na 2 HPO 4 ·2H 2 O],  N -hydroxysuccinimide (NHS) 
[C 4 H 5 NO 3 ], sodium chloride [NaCl], potassium ferricyanide 
{K 3 [Fe(CN) 6 ]}, and potassium ferrocyanide {K 4 [Fe(CN) 6 ]3H 2 O} 
were procured from Fisher Scientifi c. The 3-aminopropyl triethoxy 
silane (APTES) was purchased from Alfa-aesar. All chemicals were 
of analytical grade and were used without any further purifi cation. 
Phosphate buffered saline (PBS) solution of pH 7.0 was prepared using 
Na 2 HPO 4 ·2H 2 O (0.05 mol L −1 ) and NaH 2 PO 4 (0.05 mol L −1 ). Fresh 
PBS solution was prepared using Milli-Q water having resistivity of 
18 MΩ cm and stored at 4 °C. The CYFRA-21-1 and anti-CYFRA-21-1 
were obtained from Ray Biotech, Inc., India. These biomolecules were 
further diluted by using PBS buffer of pH 7.0. CYFRA-21-1 ELISA Kit 
was purchased from KinesisDX, USA. ELISA plate reader was from 
iMark, Bio red, USA. 
 Apparatus : The crystallinity and phase formation of the synthesized 
product were investigated via X-ray diffraction (XRD) studies [Bruker 
D-8 Advance]. A monochromatic X-ray beam with Cu Kα radiation 
( λ = 1.5406 Å) was used to record the spectrum. Particle size and 
shape of ZrO 2 nanoparticles were determined using transmission 
electron microscopy (TEM) on a JEOL JEM-2100F-TEM system. Surface 
morphology of APTES/ZrO 2 /ITO, anti-CYFRA-21-1/APTES/ZrO 2 /ITO, 
and BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO electrodes was examined 
using atomic force microscopy (AFM) on a ParkXe-100 AFM system. 
The functional groups and bonds present in APTES/ZrO 2 /ITO and 
anti-CYFRA-21-1/APTES/ZrO 2 /ITO were investigated through Fourier 
transform infrared (FT-IR) spectroscopy (Perkin-Elmer, Model spectrum 
ATR accessory) and X-ray photoelectron spectroscopy (XPS). XPS was 
carried out using a Kratos AXIS ULTRADLD and Kratos Axis-Nova XPS 
system. The cyclic voltammetry (CV) and differential pulse voltammetry 
(DPV) studies were performed on an Autolab Potentiostat (Netherlands). 
These measurements were conducted using a three-electrode system 
with ITO coated glass electrode as the working electrode, platinum 
(Pt) as the counter electrode, and silver-silver chloride (Ag/AgCl) 
as the reference electrode. A PBS solution (50 × 10 −3 M ) of pH 7.0 
containing 5 × 10 −3 M of [Fe(CN) 6 3−/4− ] as redox species was used as the 
electrolyte. 
 Collection of Saliva Samples : The saliva samples of oral cancer 
patient were obtained from Rajiv Gandhi Cancer Institute and Research 
Centre, Delhi (India). All saliva samples were collected under a protocol 
approved by Rajiv Gandhi Cancer Institute and Research Center 
Institutional Review Board (R. No. RGCIRC/IRB/60/2014) and all 
patients provided written consent. Ethical approval of the Institutional 
Ethical and Biosafety committee, DTU (R. No. BT/IEBC/2014/714) was 
also obtained. Samples were collected, processed, and stored under 
similar conditions. The unstimulated whole saliva was collected from six 
patients diagnosed for oral cancer. Table S1 (Supporting Information) 
indicates pathological data of oral cancer patients. Deionized water 
(5 mL) was used for rinsing of mouth and expectorated into sterilized 
tube, kept in ice condition. The collected saliva was centrifuged at 
2800 rcf at room temperature for 30 min after which the supernatant 
was collected in a sterilized tube and stored at −20 °C until 
further used. 
 Preparation and Functionalization of Nanostructured Monoclinic-
Zirconia (ZrO 2 ) with APTES : Nanostructrured ZrO 2 was synthesized 
by the hydrothermal method. In brief, synthesis process involved the 
following steps: 0.2  M zirconium ethoxide, 0.8  M sodium hydroxide, and 
0.1  M solution of CTAB were prepared in deionized water, separately. The 
prepared solution of CTAB was dropped into the solution of zirconium 
ethoxide with a constant stirring (300 rpm) at 60 °C for 2 h after which 
solution of sodium hydroxide was added and stirred for the next 2 h. 
The prepared solution was transferred into a Tefl on vessel and placed 
in a stainless-steel tank. This assembly was kept in an oven at 170 °C 
for 15 h for hydrothermal reaction. After completion of the reaction, 
hydrothermal reactor was allowed to cool to room temperature (25 °C). 
The precipitate obtained from the reaction was washed with deionized 
water through the centrifugation process until pH of the solution 
became neutral. Subsequently, thus-obtained slurry was dried at 100 °C 
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 Table 1.  Determination of CYFRA-21-1 concentration in saliva samples using BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO bioelectrode. 
S. No. CYFRA-21-1 concentration determined 
using ELISA [ng mL −1 ]
Peak current [mA] obtained for 
standard CYFRA-21-1 samples
Peak current samples [mA] 
obtained with saliva
% RSD
1 15.35 0.312 0.314 0.45%
2 12.50 0.305 0.292 3.08%
3 12.70 0.306 0.295 2.59%
4 13.50 0.308 0.297 2.57%
5 14.15 0.310 0.299 2.55%
6 15.55 0.312 0.294 4.20%
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overnight and annealed at 400 °C for 3 h. This product was crushed 
into fi ne powder using the mortar-pestle for further characterization. 
The schematic of the preparation of ZrO 2 nanoparticles is shown in 
Scheme  1 a. 
 Functionalization of ZrO 2 : 100 mg of ZrO 2 was added to 20 mL of 
isopropanol and sonicated to obtain a highly dispersed suspension. 
Next, 200 µL of 98% APTES was mixed and stirred at 300 rpm for 48 h at 
room temperature (25 °C). In order to remove the unbound APTES, the 
suspension was fi ltered using Whatman paper and washed thoroughly 
with deionized water. 
 Electrophoretic Deposition of Functionalized ZrO 2 on ITO Electrode 
(APTES/ZrO 2 /ITO) : APTES functionalized ZrO 2 was deposited onto the 
prehydrolyzed ITO electrode via an electrophoretic deposition (EPD) 
technique using a Genetix, GX300C instrument. Prior to deposition, a 
colloidal suspension containing 10 mg of APTES/ZrO 2 was prepared 
in 2 mL of C 2 H 5 OH and 48 mL of deionized water followed by 
ultrasonication. The ITO and platinum electrodes were kept 1 cm apart 
in this colloidal suspension. Next, a DC potential of 11 V was applied 
for 20 s for EPD of APTES/ZrO 2 onto the ITO electrode. An optimized 
surface area of the APTES/ZrO 2 /ITO electrodes was determined to be 
0.25 cm 2 . The as-prepared electrode was washed with deionized water 
and dried at room temperature (25 °C) overnight. 
 Immobilization of anti-CYFRA-21-1 over APTES/ZrO 2 /ITO Electrode : 
The anti-CYFRA-21-1 solution (50 µg mL −1 ) was prepared in PBS 
(pH = 7.0). 15 µL of anti-CYFRA-21-1 was mixed with 7.5 µL of 0.4  M 
EDC (activator) and 7.5 µL of 0.1  M NHS (coupling agent). Subsequently, 
this solution (30 µL) was uniformly spread onto APTES/ZrO 2 /ITO 
electrode by drop-casting. The electrode was kept in a humid chamber at 
room temperature (25 °C) followed by washing with PBS to remove any 
unbound antibody molecules. The COOH group of anti-CYFRA-21-1 
can be covalently bound with -NH 2 terminal of APTES via strong amide 
bond (OC-NH). Lastly, bovine serum albumin (BSA = 2 mg dL −1 ) was 
used for blocking the nonspecifi c active sites of the electrode. The BSA/
anti-CYFRA-21-1/APTES/ZrO 2 /ITO immunoelectrode was stored at 4 °C 
when not in use. Scheme  1 b shows a step-wise fabrication process of 
the BSA/anti-CYFRA-21-1/APTES/ZrO 2 /ITO immunosensor along with 
the biochemical reaction. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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Method Detection 
technique
Invasive/
noninvasive
Label Sample Biomarker Concentration range 
of biomarker
Detection limit/detection 
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Response 
time
Ref.
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SL: 6 weeks
FU
LL P
A
P
ER
(9 of 9) 1500048wileyonlinelibrary.com© 2015 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.MaterialsViews.com
www.advancedscience.com
Adv. Sci. 2015, 2, 1500048
[6]  L. L.  Patton ,  J. B.  Epstein ,  A. R.  Kerr ,  J. Am. Dental Assoc.  2008 ,  139 , 
 896 . 
[7]  S. K.  Arya ,  S.  Bhansali ,  Chem. Rev.  2011 ,  111 ,  6783 . 
[8]  L.  Wang ,  Y.  Wang ,  J. I.  Wong ,  T.  Palacios ,  J.  Kong ,  H. Y.  Yang ,  Small 
 2014 ,  10 ,  1101 . 
[9]  P. R.  Solanki ,  A.  Kaushik ,  V. V.  Agrawal ,  B. D.  Malhotra ,  NPG Asia 
Mater.  2011 ,  3 ,  17 . 
[10]  M.  Das ,  C.  Dhand ,  G.  Sumana ,  A.  Srivastava ,  N.  Vijayan , 
 R.  Nagarajan ,  B.  Malhotra ,  Appl. Phys. Lett.  2011 ,  99 ,  143702 . 
[11]  N.  Zhao ,  D.  Pan ,  W.  Nie ,  X.  Ji ,  J. Am. Chem. Soc.  2006 ,  128 ,  10118 . 
[12]  F.  Bellezza ,  A.  Cipiciani ,  M. A.  Quotadamo ,  Langmuir  2005 ,  21 , 
 11099 . 
[13]  S.  Kumar ,  S.  Kumar ,  M.  Ali ,  P.  Anand ,  V. V.  Agrawal ,  R.  John , 
 S.  Maji ,  B. D.  Malhotra ,  Biotechnol. J.  2013 ,  8 ,  1267 . 
[14]  Z.  Wang ,  J.  Zhang ,  Y.  Guo ,  X.  Wu ,  W.  Yang ,  L.  Xu ,  J.  Chen ,  F.  Fu ,  Bio-
sens. Bioelectron.  2013 ,  45 ,  108 . 
[15]  C.-Y.  Yang ,  E.  Brooks ,  Y.  Li ,  P.  Denny ,  C.-M.  Ho ,  F.  Qi ,  W.  Shi , 
 L.  Wolinsky ,  B.  Wu ,  D. T.  Wong ,  Lab Chip  2005 ,  5 ,  1017 . 
[16]  R.  Malhotra ,  V.  Patel ,  J. P.  Vaqué ,  J. S.  Gutkind ,  J. F.  Rusling ,  Anal. 
Chem.  2010 ,  82 ,  3118 . 
[17]  T.  Li ,  M.  Yang ,  Sens. Actuators B: Chem.  2011 ,  158 ,  361 . 
[18]  R.  Nagler ,  G.  Bahar ,  T.  Shpitzer ,  R.  Feinmesser ,  Clin. Cancer Res. 
 2006 ,  12 ,  3979 . 
[19]  J.  Jose ,  P.  Sunil ,  Madhavan R. Nirmal  ,  S. S.  Varghese ,  Oral Maxillo-
facial Pathol. J.  2013 ,  4 ,  368. 
[20]  K.  Rajkumar ,  R.  Ramya ,  G.  Nandhini ,  P.  Rajashree ,  Ramesh 
A. Kumar ,  Nirmala ,  S. Anandan  ,  Oral Dis.  2013 ,  21 ,  90. 
[21]  A. J.  Bandodkar ,  J.  Wang ,  Trends Biotechnol.  2014 ,  32,  363. 
[22]  J.  Matos ,  Anjos ,  F. Junior ,  L.  Cavalcante ,  V.  Santos ,  S.  Leal ,  Santos 
L. Junior ,  M.  Santos ,  E.  Longo ,  Mater. Chem. Phys.  2009 ,  117 , 
 455 . 
[23]  G.  Sumana ,  M.  Das ,  S.  Srivastava ,  B.  Malhotra ,  Thin Solid Films 
 2010 ,  519 ,  1187 . 
[24]  R. M.  Pasternack ,  Rivillon ,  S. Amy ,  Y. J.  Chabal ,  Langmuir  2008 ,  24 , 
 12963 . 
[25]  Z.  Mo ,  C.  Zhang ,  R.  Guo ,  S.  Meng ,  J.  Zhang ,  Ind. Eng. Chem. Res. 
 2011 ,  50 ,  3534 . 
[26]  S.  Srivastava ,  M. A.  Ali ,  P. R.  Solanki ,  P. M.  Chavhan ,  M. K.  Pandey , 
 A.  Mulchandani ,  A.  Srivastava ,  B. D.  Malhotra ,  RSC Adv.  2013 ,  3 , 
 228 . 
[27]  C.  Morant ,  J.  Sanz ,  L.  Galan ,  L.  Soriano ,  F.  Rueda ,  Surface Sci.  1989 , 
 218 ,  331 . 
[28]  A.  Dementjev ,  O.  Ivanova ,  L.  Vasilyev ,  A.  Naumkin ,  D.  Nemirovsky , 
 D.  Shalaev ,  J. Vac. Sci. Technol. A  1994 ,  12 ,  423 . 
[29]  M. A.  Ali ,  S.  Srivastava ,  P. R.  Solanki ,  V.  Reddy ,  V. V.  Agrawal , 
 C.  Kim ,  R.  John ,  B. D.  Malhotra ,  Sci. Rep.  2013 ,  3 ,  1. 
[30]  A.  Vasudev ,  A.  Kaushik ,  S.  Bhansali ,  Biosens. Bioelectron.  2013 ,  39 , 
 300 . 
[31]  S.  Kumar ,  J.  Singh ,  V.  Agrawal ,  M.  Ahamad ,  B.  Malhotra ,  Anal. 
Methods  2011 ,  3 ,  2237 . 
[32]  G.  Liu ,  Y.  Lin ,  Anal. Chem.  2005 ,  77 ,  5894 . 
[33]  A.  Kaushik ,  P. R.  Solanki ,  M.  Pandey ,  S.  Ahmad ,  B. D.  Malhotra , 
 Appl. Phys. Lett.  2009 ,  95 ,  173703 . 
[34]  E.  Schäfer ,  T.  Zandbiglari ,  Int. Endodontic J.  2003 ,  36 ,  660 . 
